These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37601064)

  • 21. Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials.
    Utembe W; Clewell H; Sanabria N; Doganis P; Gulumian M
    Nanomaterials (Basel); 2020 Jun; 10(7):. PubMed ID: 32610468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microphysiological systems in early stage drug development: Perspectives on current applications and future impact.
    Kopec AK; Yokokawa R; Khan N; Horii I; Finley JE; Bono CP; Donovan C; Roy J; Harney J; Burdick AD; Jessen B; Lu S; Collinge M; Sadeghian RB; Derzi M; Tomlinson L; Burkhardt JE
    J Toxicol Sci; 2021; 46(3):99-114. PubMed ID: 33642521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole body pharmacokinetic models.
    Nestorov I
    Clin Pharmacokinet; 2003; 42(10):883-908. PubMed ID: 12885263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats.
    Kamgang E; Peyret T; Krishnan K
    SAR QSAR Environ Res; 2008; 19(7-8):669-80. PubMed ID: 19061083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative systems toxicology to predict human biological systems affected by exposure to environmental chemicals.
    Taboureau O; El M'Selmi W; Audouze K
    Toxicol Appl Pharmacol; 2020 Oct; 405():115210. PubMed ID: 32860831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience.
    Moné MJ; Pallocca G; Escher SE; Exner T; Herzler M; Bennekou SH; Kamp H; Kroese ED; Leist M; Steger-Hartmann T; van de Water B
    Arch Toxicol; 2020 Oct; 94(10):3581-3592. PubMed ID: 32886186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Precision Toxicology initiative.
    PrecisionTox Consortium
    Toxicol Lett; 2023 Jul; 383():33-42. PubMed ID: 37211341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry.
    el-Masri HA; Mumtaz MM; Choudhary G; Cibulas W; De Rosa CT
    Int J Hyg Environ Health; 2002 Mar; 205(1-2):63-9. PubMed ID: 12018017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
    Watson DE; Hunziker R; Wikswo JP
    Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of industrial chemicals and pesticides for effects on human health.
    Stucki AO; Barton-Maclaren TS; Bhuller Y; Henriquez JE; Henry TR; Hirn C; Miller-Holt J; Nagy EG; Perron MM; Ratzlaff DE; Stedeford TJ; Clippinger AJ
    Front Toxicol; 2022; 4():964553. PubMed ID: 36119357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sourcing data on chemical properties and hazard data from the US-EPA CompTox Chemicals Dashboard: A practical guide for human risk assessment.
    Williams AJ; Lambert JC; Thayer K; Dorne JCM
    Environ Int; 2021 Sep; 154():106566. PubMed ID: 33934018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop.
    Felter SP; Bhat VS; Botham PA; Bussard DA; Casey W; Hayes AW; Hilton GM; Magurany KA; Sauer UG; Ohanian EV
    Crit Rev Toxicol; 2021 Sep; 51(8):653-694. PubMed ID: 35239444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Data governance in predictive toxicology: A review.
    Fu X; Wojak A; Neagu D; Ridley M; Travis K
    J Cheminform; 2011 Jul; 3(1):24. PubMed ID: 21752279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human-Based New Approach Methodologies in Developmental Toxicity Testing: A Step Ahead from the State of the Art with a Feto-Placental Organ-on-Chip Platform.
    Luconi M; Sogorb MA; Markert UR; Benfenati E; May T; Wolbank S; Roncaglioni A; Schmidt A; Straccia M; Tait S
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing integrated PBPK/PD coupled mechanistic pathway model (miRNA-BDNF): An approach towards system toxicology.
    Sharma RP; Schuhmacher M; Kumar V
    Toxicol Lett; 2017 Oct; 280():79-91. PubMed ID: 28818579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making in silico predictive models for toxicology FAIR.
    Cronin MTD; Belfield SJ; Briggs KA; Enoch SJ; Firman JW; Frericks M; Garrard C; Maccallum PH; Madden JC; Pastor M; Sanz F; Soininen I; Sousoni D
    Regul Toxicol Pharmacol; 2023 May; 140():105385. PubMed ID: 37037390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation.
    Coppola P; Kerwash E; Cole S
    Front Pediatr; 2021; 9():687978. PubMed ID: 34249817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brazil's Regulatory Context for Using New Approach Methodologies (NAMs) on the Registration of Products.
    Villela IV; Machado MDS
    Front Toxicol; 2022; 4():903027. PubMed ID: 35936389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RE-Place: A Unique Project Collecting Expertise on New Approach Methodologies.
    Van Mulders M; Liodo Missigba N; Mertens B; Rogiers V
    Front Pharmacol; 2022; 13():930148. PubMed ID: 35814243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.